Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
US10646567B2 · kind B2 · utility
1Cited by
28References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2017 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Dec 14, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.